New In-Licensed Akcea Core Technology Patents or Akcea Manufacturing and Analytical Patents. On a Product-by-Product basis, if, after the date of Option Exercise, Akcea obtains Third Party Patent Rights necessary to Develop, Manufacture or Commercialize a Product that would have been considered an Akcea Core Technology Patent or an Akcea Manufacturing and Analytical Patent had Akcea Controlled such Patent Rights on the Effective Date, Akcea will include such Third Party Patent Rights in the license granted to Novartis under Section 5.1.1 or Section 5.1.2 (as applicable) and any and all costs arising under such Third Party agreement as they apply to a Product will be paid solely by [***] as [***].
Appears in 4 contracts
Samples: Strategic Collaboration, Option and License Agreement (Ionis Pharmaceuticals Inc), Option and License Agreement (Akcea Therapeutics, Inc.), Option and License Agreement (Akcea Therapeutics, Inc.)
